Opdivo-Yervoy (nivolumab-ipilimumab)

Numéro de dossier de l’APP: 21710
État des négociations:
Concluded with an LOI
Indication(s):
Nivolumab, in combination with ipilimumab and 2 cycles of platinum-based chemotherapy for the first-line treatment of patients with metastatic or recurrent NSCLC with no EGFR or ALK genomic tumor aberrations
Promoteur/fabricant:
Bristol Myers Squibb Canada Inc.
Numéro de projet de l’ACMTS:
PC0218
Lettre-contrat de l’APP:
Conclusion du processus de négociation: